We are excited to be participating in the 2018 American Society of Clinical Oncology (ASCO) annual meeting. The meeting takes place in Chicago, Illinois, June 1-5, 2018.

David Meek, CEO, and Alexandre Lebeaut, CSO, invite you to the Ipsen Neuroendocrine Tumor (NET) Expert Call

On Wednesday 21st February, the Ipsen Dublin team accepted their Great Place to Work certificate, officially recognizing the site as one of the Best Medium Workplaces in Ireland. The event was attended by almost 900 people, representing 85 companies from across all business sectors.

In the pivotal phase 3 CELESTIAL trial, CABOMETYX provided a statistically significant and clinically meaningful improvement versus placebo in overall survival (OS) 

February 15th is International Childhood Cancer Day. It is a global collaborative campaign to raise awareness about childhood cancer and to express support for children and adolescents with cancer and their families.

Ipsen announced its corporate agenda* for 2018:

The Fondation IPSEN announce the appointment of Dr James A. Levine as its new President, effective from November 3rd 2017.

On December 7th, Ipsen’s affiliate in Algeria and its Algerian partner Isly Holding, signed an agreement for the creation of a mixed Algerian-French company. This will be in accordance with the Rule 49/51 governing foreign investment in Algeria.

For the last 6 years Ipsen, with around 15 teams each year worldwide, has been supporting Movember to change the face of men’s health and raise funds for the Movember Foundation.

NET Cancer Day on the 10th of November 2017, is an annual event dedicated to raising awareness of a rare cancer, neuroendocrine tumors (NET).

We are excited to be participating in the 2017 ESMO congress in Madrid from the 8th until the 12th of September. Discover all activities Ipsen is organising and data we are sharing at this year’s congress.

Access the audio webcast of the first half 2017 financial results.
DAVID MEEK, CEO
AYMERIC LE CHATELIER, EXECUTIVE VICE PRESIDENT, FINANCE
WILL BE PRESENTING IPSEN’S FIRST HALF 2017 FINANCIAL RESULTS ON THURSDAY 27TH JULY 2017.

Thursday, May 11: a unique opportunity to hear about our strategy for 2017 and beyond.

What is a clinical trial?
What are the different kinds of clinical trials?
What’s the best way to find a clinical trial?

Access Ipsen’s 2016 results press conference and financial webcast.

Ipsen announced on January 9, 2017 that it has entered into a definitive agreement to acquire global oncology assets from Merrimack Pharmaceuticals, including its key marketed product ONIVYDE®.

Nearly 900 patient questionnaires across the globe were collected to assess the needs and wants for patients living with NETs and create this website. From the pre-diagnosis stage right up to living long term with the illness, this disease awareness website has been created for patients and designed with them.

Ipsen and its partner Exelixis held a conference on October 10^th during ESMO congress (European Society of Medical Oncology) to present the latest developments on cabozantinib and the Cabosun trial.

On 1st August 2016 the U.S. Food and Drug Administration (FDA) has approved Dysport^® (abobotulinumtoxinA) for injection for the treatment of pediatric lower limb (PLL) spasticity in children two years of age and older. Dysport^® is the First and only FDA-approved botulinum toxin for the treatment of pediatric lower limb spasticity.

July, 22 2016. The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA) provided a positive opinion for Cabometyx^TM (cabozantinib) 20, 40, 60mg for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy and recommended it for marketing authorization.

January, 8 2016 – Ipsen and Aepodia have signed a partnership for early-stage development programs in R&D: Aepodia will provide its expertise and agility in early clinical development and in the implementation of Phase I studies up to Proof-of-Concept (POC). Aepodias’s team will work with Ipsen teams to optimize the design of clinical studies and their operational implementation.

October 14, 2015 – Ipsen has celebrated today the grand opening of its new Canadian headquarters in Mississauga, Ontario in presence of Marc Trouyet, Consul General of France in Toronto, Hon. Dipika Damerla, Member of the Provincial Parliament for Mississauga-East Cooksville and Associate Minister for Health and Long Term Care in the Ontario Provincial, Marc de Garidel, Chairman and CEO of Ipsen, Cynthia Schwalm, President and CEO of Ipsen North America, and Lyndal Walker, Country Manager of Ipsen Canada.

Ipsen launched on July 22, a manufacturing contract in Russia at the site of “Raduga Production” in St Petersburg, part of pharmaceutical Group ROSTA. The first step of the joint project will be the manufacturing of Tanakan® with a planned annual output of approximately 120 million tablets.

Marc de Garidel interview, Chairman and Chief Executive Officer.

To mark the occasion of the opening of its new R&D center in the US, Ipsen hosted on April 1st an international scientific symposium dedicated to “Creativity and Innovation”, where pioneering scientists coming from different horizons and approaching creativity in different ways delivered lectures.